Associated tags: Diamond, BRAF, CNS, GBM, EGFR, Brain, RAF, NRAS, Therapy, NSCLC, Patient, Cancer, Pharmaceutical industry, M26 Modular Accessory Shotgun System, Black Diamond, Conference, MAP, Drug discovery
Locations: ARIZONA, KRAS, SD, PK, TD, CHICAGO, IL, CAMBRIDGE, MA, US, BLACK DIAMOND, RIBON
Diamond,
FDA,
Cancer,
Foundation Medicine,
Mutation,
Investment,
HGG,
Food,
Research,
Lung cancer,
GBM,
Development,
Administration,
ASCO,
TKI,
Helmy Eltoukhy,
BRAF,
Patient,
Society,
G&A,
AACR,
Annual general meeting,
Prevalence,
NRAS,
Pharmaceutical industry Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.
Key Points:
- Cash Position: Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents, and investments compared to $131.4 million as of December 31, 2023.
- Net cash used in operations was $21.2 million for the first quarter of 2024 compared to $20.0 million for the first quarter of 2023.
- Net Loss: Net loss for the first quarter of 2024 was $18.2 million, as compared to $20.9 million for the same period in 2023.
- Black Diamond ended the first quarter of 2024 with approximately $115.2 million in cash, cash equivalents and investments which the Company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.
Retrieved on:
Wednesday, April 24, 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.
Key Points:
- CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced forthcoming presentations during the 2024 ASCO Annual Meeting, taking place May 31 – June 4 in Chicago, IL.
- The two poster presentations describe data for BDTX-1535 in patients with recurrent glioblastoma (GBM) across two clinical trials: a Phase 1 dose escalation trial, for which topline data were released in December 2023 , and a Phase 0/1 “trigger” (“window of opportunity”) trial conducted as an Investigator Sponsored Trial at the Ivy Brain Tumor Center ( NCT06072586 ).
- Presentation details are as follows:
Title: Phase 1 Study of BDTX-1535, an Oral 4th Generation Covalent EGFR Inhibitor, in Patients with Recurrent Glioblastoma: Preliminary Dose Escalation Results
Posters will become available on June 1, 2024 at 10:00 AM EDT on the Black Diamond Therapeutics website here .
Diamond,
Bayer,
University,
Executive,
Ithaca College,
University of Pennsylvania,
Flagship Pioneering,
Scripps Research,
Pharmacia,
Harvard Business School,
Novartis,
Therapy,
Abbott Laboratories,
IMD,
Patient,
Medicinal chemistry,
Immunology,
Takeda Oncology,
EGFR,
Cancer,
NSCLC,
Partnership,
Management The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors.
Key Points:
- The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors.
- “On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncology expertise to our board as we advance BDTX-1535, a potential first and best-in-class fourth-generation EGFR inhibitor,” said Mark Velleca, M.D., Ph.D., Chief Executive Officer of Black Diamond Therapeutics.
- He currently serves as Chief Executive Officer of a stealth biopharma company working on novel protein therapeutics in Oncology and Immunology.
- Previously, he was President and Chief Executive Officer of Ribon Therapeutics, a biopharmaceutical company focused on small molecule drugs for Oncology and Immunology.
Diamond,
EGFR,
Helmy Eltoukhy,
Mutation,
Prevalence,
NSCLC,
Survival,
Foundation Medicine,
Patient,
Cancer,
Lung cancer,
AACR,
PACC,
TKI,
Drug resistance,
MD Anderson Cancer Center,
Associate professor CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell lung cancer (NSCLC), and the potential of BDTX-1535 to address a broader range of mutations compared to existing therapies. The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
Key Points:
- The results were disclosed in an oral presentation on April 7, 2024, at the 2024 American Association of Cancer Research (AACR) Annual Meeting held in San Diego, California.
- The analyses reveal a broad spectrum of non-classical mutations, as well as an increased prevalence of the acquired resistance mutation, C797S.
- The compound also potently inhibits the drug resistance C797S mutation, which emerges following treatment with third-generation EGFR inhibitors, including osimertinib.
- Black Diamond is currently advancing BDTX-1535 in a Phase 2 trial for patients with EGFRm NSCLC across multiple lines of therapy.
Key Points:
- CAMBRIDGE, Mass.
- and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences.
- Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com .
- Replays of the presentations will also be available and archived on the site for 90 days.
Diamond,
Research,
Administration,
EGFR,
Mutation,
RAF,
Development,
HGG,
Patient,
GBM,
Neoplasm,
Cancer,
Lung cancer,
BRAF,
AACR,
Treatment,
Investment,
NRAS,
Clinical trial,
Therapy,
Poster,
FDA,
Food,
Pharmaceutical industry The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.
Key Points:
- The presentation included clinical data from 27 patients with advanced/metastatic NSCLC who received once daily doses ranging from 25mg to 400mg.
- The trial is currently in dose escalation with an update anticipated in the fourth quarter of 2024.
- (NCT05786924)
Cash Position: Black Diamond ended 2023 with approximately $131.4 million in cash, cash equivalents, and investments compared to $122.8 million as of December 31, 2022.
- Net Loss: Net loss for the fourth quarter of 2023 was $19.4 million, as compared to $21.1 million for the same period in 2022.
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced an upcoming oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
Key Points:
- CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced an upcoming oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
- The presentation will describe real world data of the evolving EGFR mutation landscape in patients with NSCLC, highlighting the increasing relevance of “non-classical” EGFR mutations, which can be found in up to 30% of EGFRm NSCLC.
- The presentation will also describe the profile of BDTX-1535, an oral, brain-penetrant MasterKey inhibitor that selectively targets more than 50 oncogenic EGFR mutations.
- Title: BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC
Retrieved on:
Wednesday, February 28, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m.
Key Points:
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today announced that its Chief Executive Officer, Mark A. Velleca, M.D., Ph.D., will participate in a panel discussion on lung cancer at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 9:10 a.m.
- ET in Boston, MA.
- A live webcast of the panel can be accessed by visiting the investor relations section of the Company’s website at: www.blackdiamondtherapeutics.com .
- A replay of the webcast will also be available and archived for 90 days following the event.
Retrieved on:
Thursday, January 4, 2024
Diamond,
Conference,
AACR,
Food,
FDA,
EGFR,
Cancer,
Therapy,
Clinical trial,
RAF,
GBM,
RAS,
Patient,
Pharmaceutical industry CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today provided a corporate update outlining clinical development plans and anticipated corporate milestones for 2024.
Key Points:
- CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today provided a corporate update outlining clinical development plans and anticipated corporate milestones for 2024.
- “In 2024, we anticipate key readouts from each of these programs, including Phase 2 data from BDTX-1535 in NSCLC.
- Phase 2 data in second/third-line patients with EGFR mutant NSCLC are expected in the third quarter of 2024.
- Results from this trial are expected to be presented at a medical meeting in the second quarter of 2024.
Retrieved on:
Wednesday, December 13, 2023
Diamond,
Patient,
Conference,
Lung cancer,
AACR,
Temozolomide,
PR,
Neoplasm,
Diarrhea,
EGFR,
Dana–Farber Cancer Institute,
Neuro-Oncology (journal),
Brain,
Therapy,
Clinical trial,
PD,
Bevacizumab,
CNS,
Cancer,
GBM,
Diagnosis,
Safety,
PFS,
NSCLC,
Rash,
Pharmaceutical industry BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or GBM.
Key Points:
- BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or GBM.
- Clinical data as of November 2023 reflect 27 patients with recurrent GBM who received a range of doses spanning 15mg to 400mg once daily (QD) in the dose escalation cohort.
- Of the 27 patients with recurrent GBM, 22 were started at or escalated to a dose of 100mg QD or greater and reached at least one post baseline tumor assessment.
- Black Diamond plans to submit results from the dose escalation GBM cohort for presentation at a medical meeting in the second quarter of 2024.
